New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
09:56 EDTAERI, ERIC, PRXL, PE, STBZ, STLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aerie Pharmaceuticals (AERI) initiated with a Buy at Canaccord... Alliance Fiber Optic (AFOP) initiated with a Buy at Sidoti... Ericsson (ERIC) initiated with a Hold at Jefferies... PAREXEL (PRXL) initiated with a Hold at KeyBanc... Parsely Energy (PE) initiated with a Sector Perform at RBC Capital... State Bank Financial (STBZ) initiated with a Buy at Wunderlich... Sterling Bancorp (STL) initiated with an Outperform at Raymond James.
News For AERI;ERIC;PRXL;PE;STBZ;STL From The Last 14 Days
Check below for free stories on AERI;ERIC;PRXL;PE;STBZ;STL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
11:18 EDTSTLSterling Bancorp management to meet with Sterne Agee
Subscribe for More Information
July 29, 2014
10:01 EDTERICEricsson agrees to acquire MetrTech Corp.
Subscribe for More Information
July 28, 2014
17:57 EDTSTLSterling Bancorp reports Q3 core EPS 19c vs. 15c a year ago
Subscribe for More Information
July 24, 2014
07:33 EDTAERIAerie receives NOL for Rhopressa Phase 3 registration trial
Aerie Pharmaceuticals announced that it has received a No Objection Letter from Health Canada to conduct a Phase 3 registration trial of Rhopressa. The study, named “Rocket 3,” is designed to evaluate safety and tolerability of Rhopressa in patients over 12 months and is part of a broad Phase 3 program being conducted by Aerie. The company recently announced the commencement of two Phase 3 trials in the U.S., “Rocket 1” and “Rocket 2,” which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa. The company said, " Pending progress of the program and regulatory approvals, Aerie intends to commercialize Rhopressa in North American markets with its own sales force and will seek commercialization partners in other key territories, including Europe and Japan. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030."
07:11 EDTSTBZState Bank Financial reports Q2 EPS 22c, consensus 18c
Subscribe for More Information
July 22, 2014
06:11 EDTERICEricsson selected by Claro in Costa Rica
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use